Lineage Cell Therapeutics, Inc. (LCTX) has disclosed a new risk, in the Supply Chain category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lineage Cell Therapeutics, Inc. faces added regulatory and commercialization risk because key programs rely on pluripotent cell lines that may be exempt from certain contemporary donor eligibility requirements, potentially triggering special labeling, added conditions, or use limitations. If regulators later deem historical donor screening or testing practices for these hES or iPSC lines insufficient, the company could be forced to perform additional studies, enhance manufacturing controls, or even halt affected programs, which would negatively impact its overall business and development prospects.
The average LCTX stock price target is $9.00, implying 386.49% upside potential.
To learn more about Lineage Cell Therapeutics, Inc.’s risk factors, click here.